Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis [8]

Leukemia

Volumn 22, Issue 3, 2008, Pages 649-652

  Brownlow, N ^a   Russell, A E ^a   Saravanapavan, H ^a   Wiesmann, M ^b   Murray, J M ^b   Manley, P W ^b   Dibb, N J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR; IMATINIB; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PROTEIN KINASE B;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; BONE METASTASIS; CELL STIMULATION; COLONY FORMATION; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FIBROBLAST; GENE MUTATION; HUMAN; IC 50; LETTER; MACROPHAGE ACTIVATION; NONHUMAN; OSSIFICATION; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; STEM CELL;

EID: 40749128890     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404944     Document Type: Letter

References (19)

1. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005; 1754: 3-13.
2. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765-1769.
3. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006-2013.
4. Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006; 25: 147-151.
5. Roussel MF, Dull TJ, Rettenmier CW, Ralph P, Ullrich A, Sherr CJ. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature 1987; 325: 549-552.
6. Morley GM, Uden M, Gullick WJ, Dibb NJ. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene 1999; 18: 3076-3084.
7. Ando W, Hashimoto J, Nampei A, Tsuboi H, Tateishi K, Ono T et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J. Bone Miner Metab 2006; 24: 274-282.
8. El Hajj Dib I, Gallet M, Mentaverri R, Sevenet N, Brazier M, Kamel S. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol 2006; 551: 27-33.
9. Schubert C, Schalk-Hihi C, Struble GT, Ma HC, Petrounia IP, Brandt B et al. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J Biol Chem 2006; 282: 4094-4101.
10. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN et al Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004; 279: 31655-31663.
11. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
12. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003; 17: 1713-1721.
13. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102: 16078-16083.
14. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757-766.
15. Dewar AL, Farrugia AN, Condina MR, Bik To L, Hughes TP, Vernon-Roberts B et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood 2006; 107: 4334-4337.
16. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M et al A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006; 5: 2634-2643.
17. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78.
18. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ. A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J 2006; 20: 1921-1923.
19. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-593.